Finance

Lists
AUROPHARMA:NSE
Aurobindo Pharma Ltd
1 666,90 INR
-0,66%
(-11,00) 1D
16 ოქტ, 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for AUROPHARMA...
Open
1 677,90 INR
High
1 681,70 INR
Low
1 655,00 INR
Mkt. cap
959,10 მლრ.
Avg. vol.
778,73 ათ.
Volume
796,73 ათ.
P/E ratio
26,04
52-wk high
1 740,00 INR
52-wk low
1 080,10 INR
EPS
64,00 INR
Shares outstanding
585,90 მლნ.
No. of employees
29 ათ.
Open
1 677,90 INR
High
1 681,70 INR
Low
1 655,00 INR
Mkt. cap
959,10 მლრ.
Avg. vol.
778,73 ათ.
Volume
796,73 ათ.
P/E ratio
26,04
52-wk high
1 740,00 INR
52-wk low
1 080,10 INR
EPS
64,00 INR
Shares outstanding
585,90 მლნ.
No. of employees
29 ათ.
News stories
From web sources and news partners
Profile
Aurobindo Pharma Limited is an Indian multinational pharmaceutical manufacturing company based in HITEC City, Hyderabad, with U.S. headquarters in East Windsor, Mercer County, New Jersey. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's area of activity includes six major therapeutic and product areas: antibiotics, anti-retrovirals, cardiovascular products, central nervous system products, gastroenterologicals, and anti-allergics. The company markets these products in over 125 countries. Its marketing partners include Pfizer and AstraZeneca. Wikipedia
About Aurobindo Pharma Ltd
CEO-
Employees29,2 ათ.
Founded1986
Headquartersჰაიდარაბადი, ანდჰრა-პრადეში, ინდოეთი
SectorPharmaceutical industry
Websiteaurobindo.com
Last report
6 აგვ. 2026
Fiscal period
Q1 2027
17,46 INR / 17,26 INR
+1,17%beat
Revenue / Est. (INR)
91,50 მლრდ. / 89,98 მლრდ.
+1,69%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
82,86 მლრდ.
86,46 მლრდ.
88,53 მლრდ.
91,50 მლრდ.
Cost of goods sold
33,39 მლრდ.
34,81 მლრდ.
39,28 მლრდ.
36,27 მლრდ.
Cost of revenue
33,39 მლრდ.
34,81 მლრდ.
39,28 მლრდ.
36,27 მლრდ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
12,77 მლრდ.
13,10 მლრდ.
14,31 მლრდ.
14,80 მლრდ.
Operating expense
36,98 მლრდ.
38,56 მლრდ.
35,29 მლრდ.
41,29 მლრდ.
Total operating expenses
70,37 მლრდ.
73,37 მლრდ.
74,57 მლრდ.
77,56 მლრდ.
Operating income
12,49 მლრდ.
13,09 მლრდ.
13,96 მლრდ.
13,94 მლრდ.
Other non operating income
1,16 მლრდ.
1,54 მლრდ.
-2,51 მლრდ.
2,12 მლრდ.
EBT including unusual items
12,76 მლრდ.
13,39 მლრდ.
12,91 მლრდ.
15,15 მლრდ.
EBT excluding unusual items
12,76 მლრდ.
14,04 მლრდ.
13,59 მლრდ.
15,55 მლრდ.
Income tax expense
4,28 მლრდ.
4,29 მლრდ.
3,70 მლრდ.
4,83 მლრდ.
Effective tax rate
33,53%
32,03%
28,65%
31,88%
Other operating expenses
19,91 მლრდ.
20,81 მლრდ.
16,37 მლრდ.
21,62 მლრდ.
Net income
8,48 მლრდ.
9,10 მლრდ.
9,21 მლრდ.
10,33 მლრდ.
Net profit margin
10,24%
10,53%
10,41%
11,28%
Earnings per share
14,61
16,43
15,86
17,46
Interest and investment income
-
-
3,31 მლრდ.
-
Interest expense
-952,40 მლნ.
-927,70 მლნ.
-665,50 მლნ.
-1,02 მლრდ.
Net interest expenses
-952,40 მლნ.
-927,70 მლნ.
2,65 მლრდ.
-1,02 მლრდ.
Depreciation and amortization charges
4,29 მლრდ.
4,65 მლრდ.
4,61 მლრდ.
4,87 მლრდ.
EBITDA
16,66 მლრდ.
16,71 მლრდ.
18,03 მლრდ.
18,01 მლრდ.
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები